Company Overview
Moolec Science SA, a science-based ingredient company, engages in the development of ingredients for food, pet food, animal feed, and dietary supplements using molecular farming technology and precision fermentation platforms in Cayman Islands and internationally. It develops nutritional supplements, food ingredients, meat replacements, and by-products using safflowers, chickpeas, fungi, soybeans, and yeast, as well as lupin and peas. The company is based in Grand Cayman, Cayman Islands.
Recent Developments
- Jun 2025 Revenue of $333.61M (-28.5% YoY); net profit $-111.46M.
- Trailing 12 Months Year-on-year growth — revenue -28.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -28.47% |
Stock Price Performance
| 1 Year: | -82.83% |
| 6 Months: | -22.74% |
| 3 Months: | -2.94% |
| 1 Month: | -3.62% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)47.67 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 82.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MLEC Moolec Science SA PHARMA | 6.93 | -0.03 | $5.03M | 0.00% | 11.20% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 |
|---|---|
| Revenue | 2.64M |
| Cost of Revenue | 3.32M |
| Gross Profit | -674.37K |
| Operating Expenses | 1.39M |
| Operating Income | -2.06M |
| EBITDA | -1.33M |
| Interest Expense | 664.02K |
| Pretax Income | -2.15M |
| Tax Provision | 280.89K |
| Net Income | -2.43M |
| Diluted EPS | -9.00 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 0 | 420.87M | 466.38M | 333.61M |
| Cost of Revenue | 0 | 241.65M | 287.06M | 207.87M |
| Gross Profit | 0 | 179.22M | 179.31M | 125.74M |
| Operating Expenses | 3.65M | 128.61M | 137.55M | 129.25M |
| Operating Income | -3.65M | 50.61M | 41.76M | -3.51M |
| EBITDA | -4.52M | 100.87M | 29.16M | -109.67M |
| Interest Expense | 2.13K | 30.57M | 35.78M | 38.08M |
| Pretax Income | -4.53M | 50.79M | -27.96M | -170.00M |
| Tax Provision | 0 | -2.33M | 1.10M | 6.64M |
| Net Income | -4.53M | 40.44M | -32.69M | -111.46M |
| Diluted EPS | -18.08 | 132.05 | -28.50 | -258.69 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Total Assets | 5.69M | 24.05M | 949.84M | 204.71M |
| Current Assets | 1.08M | 5.33M | 438.21M | 31.19M |
| Cash & Equivalents | 1.08M | 2.53M | 52.99M | 767.92K |
| Inventory | 0 | 465.75K | 126.22M | 2.24M |
| Receivables | 0 | 361.10K | 209.01M | 6.09M |
| Total Liabilities | 4.09M | 13.95M | 699.84M | 287.58M |
| Current Liabilities | 4.09M | 12.60M | 427.40M | 236.05M |
| Long Term Debt | - | 99.05K | 208.06M | 19.61M |
| Total Debt | - | 2.65M | 453.85M | 246.88M |
| Total Equity | 1.60M | 10.11M | 1.21M | -65.97M |
| Shares Outstanding | 250.40K | 250.43K | 256.27K | 726.93K |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -1.89M | -41.16M | 39.56M | 3.64M |
| Investing Cash Flow | 0 | -25.59M | -27.40M | -35.99M |
| Financing Cash Flow | 2.00M | 76.22M | -1.49M | -15.02M |
| Capital Expenditure | - | -22.93M | -25.03M | -14.62M |
| Free Cash Flow | -1.89M | -64.09M | 14.53M | -10.98M |
| Net Change in Cash | 114.02K | 9.47M | 10.66M | -47.37M |
Ratios (Annual)
Figures in %.
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|
| Gross Margin % | - | 42.6% | 38.4% | 37.7% |
| Operating Margin % | - | 12.0% | 9.0% | -1.1% |
| Net Margin % | - | 9.6% | -7.0% | -33.4% |
| ROE % | -282.2% | 400.1% | -2,695.0% | 169.0% |
| ROCE % | -227.7% | 441.9% | 8.0% | 11.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | UBS Group AG | 0.06% | 470 | $2.87K |
| 2 | SBI Securities Co., Ltd. | - | 1 | $6 |
| 3 | Caitong International Asset Management Co., Ltd | - | 10 | $60 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MLEC
Precision Trading with MLEC Company (MLEC) Risk Zones - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxNQWFWM3lWWjJjODVWaTlvbTBtRmhuTURwRThueGJtSzcyMXdTdFZYaUlZWHZPd0dsYXJvVjl0bmd4ZkFJQTdmbkNiVE9sWHlTRG1Eanpfc2VnYXNBczczcFlTWURNSEh4ZUVVWEFnVndxaGhwR01NeTM1YUsweUhaY1JDaTJhZG9xWTVZX3…
Why Did This Nano-Cap Food Stock More Than Double In Value Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQQ2ZSQlJyYTFXOGpMNjRhZzBLemNDNm1MY0NaVEQtbk1taHRrXzZMZ1E5d2taUTlZSm02NllpWnZVSnpOa0V2aHdVbGhBOThrTUZhRkxibUtYM1JRR0w5ZXlfbVk4UkpBVkF5SlZURkIzdV9ldi1qZlBtSGY5ckRDUHZhdzFqaTJiTy1ZR2…
Cash squeeze and disputed $2.3M claim deepen risk at Moolec (NASDAQ: MLEC) - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQSDQtTXFlZ0pmaDZJSjVBQktBSnlPMHF1NnA0SzF3U09ZMF9ROGdGMy1oMTd4LUI1NEg2LU1VS3FGOVZ3OE9kMklKRkVlaG0zR1RSUXhIQU9zcENDaDhUWjVTOTNHYTJPM0tmekhEZEtGM0FUSmtXNE1QT1QxTUJWQ0dmS1VCc2FGQVU5dV…
Moolec Science Warns of Heightened Going-Concern Risk Amid Legal Fee Dispute and Loss of Shareholder Support - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMioAJBVV95cUxQZVRFOTAyVFhTX3NiYjU4eW4walBLOEtsaTJsYlRabFI5ZUhCdXNxRUxLSE5KNnVFOV92SkpMWjdxME9mSlpYVDRvVzV1b0lHelI2M3MyWTNkN2E0el9WRmNoMlNhMjF6LTRrbnpZdlRMUGdPYVVxbFZRLTkzWGdzeTZXbHN1cjhhbWkyUl…
Moolec Science Stock (MLEC) Opinions on Molecular Farming Breakthrough - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPSnN1aUFvRGRlY0lwVlpfYXVqTzRBd2h1ZnNOSEEwVC1RZ21YNThXUEZKSk04Zm4yeXR5a2FCRlNqRU41S0FXZTlRUllXUF84aUVqaGlxVEo3Y1VvaEZValpIVjFpa3hIb0dTTTljRlVyVjBKUGNmZjNicWZwMDZkbVR0eUsxYl9yZWRQM2…
Moolec Science Granted Nasdaq Listing, Plans to Meet Requirements - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFB5cVAxUWNGR0xrUFN1SEdqT3RCZnpIQk82MjFoaWhYZUxCV0Judm9ROFFPREYxTTZ4NTBpSDZ2UTJQUlh0eW1NUE5TclRTTFo3N1Vlb20ySThrQ3I5RGgyOFZkZWduZFhvWUpERGkwd0FTaXRSOV80OGFR?oc=5" target="_blank">Moo…
MLEC — Frequently Asked Questions
What is the current share price of Moolec Science SA (MLEC)?
As of 2026-09-19 21:16 PDT, Moolec Science SA (MLEC) trades at $6.93 on NasdaqCM. Its 52-week range is $3.38 to $40.35.
What is the market capitalisation of MLEC?
Moolec Science SA (MLEC) has a market capitalisation of $5.03M on NasdaqCM.
What is the P/E ratio of MLEC?
MLEC trades at a trailing price-to-earnings (P/E) ratio of -0.03. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 8.73.
Is MLEC a good stock to buy?
This page provides a data-driven analysis of Moolec Science SA (MLEC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.